Table 3 Univariate survival analysis of S1PR1/pSTAT3 expression and clinicopathologic variables for overall survival in rituximab-treated DLBCL patients (total cohort) and clinicopathologic subgroups
Clinicopathologic variables | P values in each group*by univariate analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|  | Rituximab –treated DLBCL (total cohort) (N =103) | Primary site | Stage | IPI†| Hans classification†| ||||
|  |  | Nodal subgroup (n = 37) | Extranodal (n = 66) | Low stage (n = 47) | High stage (n = 56) | Low (0–2) (n = 60 ) | High (3–5) (n = 36 ) | GCB (n = 37) | Non-GCB (n = 62) |
Age >60 | 0.019 | 0.027 | NS (0.239) | NS (0.050) | NS (0.223) | NS (0.141) | NS (0.391) | NS (0.052) | 0.036 |
Stage (III, IV) | 0.016 | 0.034 | NS (0.145) | NA | NA | NS (0.147) | NS (0.110) | NS (0.652) | NS (0.008) |
High IPI (3–5) | 0.009 | 0.039 | NS (0.087) | <0.001 | 0.339 | NA | NA | NS (0.104) | 0.047 |
B symptoms | 0.014 | NS (0.576) | 0.002 | NS (0.481) | 0.038 | NS (0.836) | NS (0.052) | NS (0.569) | 0012 |
High LDH | 0.016 | NS (0.078) | NS (0.063) | NS (0.083) | NS (0.376) | NS (0.585) | NS (0.157) | NS (0.955) | 0.002 |
BM involvement | NS (0.663) | NS (0.790) | NS (0.323) | NS | NS (0.711) | NS (0.418) | NS (0.362) | NS (0.326) | NS (0.478) |
No. of extranodal sites | NS (0.959) | NS (0.175) | NS (0.556) | NS | NS (0.116) | NS (0.787) | 0.026 | NS (0.701) | NS (0.662) |
ECOG PS | NS (0.115) | NS (0.528) | NS (0.147) | NS (0.264) | NS (0.540) | NS (0.531) | NS (0.679) | 0.006 | NS (0.756) |
Hans classification | NS (0.764) | NS (0.118) | NS (0.429) | NS (0.336) | NS (0.404) | NS (0.789) | NS (0.709) | NA | NA |
S1PR1 | 0.018 | 0.041 | NS (0.127) | NS (0.880) | 0.002 | NS (0.347) | 0.014 | NS (0.092) | NS (0.238) |
pSTAT3 | NS (0.713) | NS (0.536) | NS (0.996) | 0.022 | NS (0.267) | NS (0.067) | NS (0.248) | NS (0.143) | NS (0.256) |
S1PR1/pSTAT3 risk category | 0.010 | NS (0.079) | NS (0.254) | NS (0.059) | 0.006 | NS (0.055) | 0.034 | NS (0.136) | NS (0.498) |